Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback